Morihepamin Ajinomoto infusion solution for cerebral syndrome (200ml)

Dosage form Package x 200ml
Specifications L-iSoleucine, L-Leucin, L-lysine acetate, L-Methionin, L-Phenylalanine, L-Threonin, L-Tryptophan, L-Valine, L-Aginin, L-Aginin, L-ASPARTIC Acid, L-Histidin, L-Serine, L-Serine, L-Tyrosin, Glycin, Glycin, Glycin

Ingredient

Composition information	Content
L-ISOLEUCINE	0.920g
L-leucin	0.945g
L-lysine acetate	0.395g
L-Methionin	0.044g
L-phenylalanine	0.030g
L-Threonin	0.214g
L-tryptophan	0.07g
L-Valine	0.890g
L-alanin	0.840g
L-Arginin	1.537g
L-ASPARTIC Acid	0.02g
L-histidin	0.31g
L-Prolin	0.53g
L-Serine	0.26g
L-Tyrosin	0.04g
Glycin	0.54g

Uses

indications

Morihepamine 200 ml is indicated in the following cases:

Support treatment in cerebral brain syndrome for patients chronic liver failure .In mice, chronic liver dysfunction caused by carbon tetrachloride, morhepamine improves neurological symptoms, reduces plasma ammonia levels and reduces coma caused by ammonia. The same results have been obtained with dog vein and lower venous connection.

The effects of improving brain electrical, free amino acid levels in plasma and brain and amino metabolism in the brain

In mice with the portal connectors of the door and the lower venous veins, Morihepamine reduces the abnormal brain caused by ammonia. Morihepamine also improves indoleamine metabolism in plasma and brain by reducing the concentration of ammonia in the blood and improving plasma fischer ratio.

Mechanism of increasing the speed of ammonia metabolism

Morihepamin is considered to quickly improve ammonia metabolism by increasing the secretion of ammonia through the kidneys in addition to activating the urea cycle in the liver and increasing the synthesis of glutamine in the brain and muscle.

Dynamic pharmacokinetics

Amino acid levels in plasma and elimination in urine have been studied in 500 ml and 1000 ml intravenous trials in healthy men. The concentration of the total amount of amino acids in plasma is maximized right after the end of the infusion, then decreases rapidly and returns to normal value after 24 hours. The form of amino acids in contrast blood reflects the amino acid component of Morihepamine. For urine elimination, it has been recognized as an increase in the volume of amino acids excreted in urine (Threonine, Serine, Glycine, Histidine and Lysine) in proportion to the volume of MoriHepamine used.

Before taking Morihepamin Ajinomoto infusion solution for cerebral syndrome (200ml)

How to use

morhepamin use intravenously.

Dosage

Morihepamine is often used for intravenous dripping with a single dose of 500 ml in adults. The transmission time is usually not less than 180 minutes for 500 ml in adults.

When intravenous infusion, 500 ml can be mixed into a solution containing carbohydrates and continuous transmission for 24 hours. The dose can be adjusted depending on age, symptoms and weight.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using MoriHepamin 200 ml , you may experience unwanted effects (ADR).

out of 243 cases of monitoring side effects before the approved drug, the total side effects are 9 (3.7%) reported in 9 cases (3.7%). The usual side effects at the time of approved drugs are nausea, vomiting (0.8% per type), sweating, increasing the concentration of blood ammonia, blood vessel pain, urticaria, limb tremor due to hypoglycemia (0.4% per type).

Unknown frequency from 0.1% to less than 5% vomit. Blood.

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Morihepamin 200 ml contraindicated in the following cases:

Patients with severe renal dysfunction (the residue of nitrogen -containing compounds can worsen symptoms).

Patients with amino acid metabolic disorders in addition to liver disorders (amino acid imbalance may be increased).

Be cautious when using

Need kidney when using morhepamine should be used for the following patients:

Patients with severe blood acidosis (large amounts can worsen blood acidosis).

Patient heart failure congestion (increased blood flow may increase the stress for the heart).

Should stop taking this medication or switch to other treatments if the medication has increased the concentration of blood ammonia and more severe mental and mental symptoms.

Used for older people

The physiological functions in the elderly often decrease, so they must be cautious when used; For example, the dose reduction.

used for children

Safety when used for children has not been confirmed (because there is no clinical trial).

The ability to drive and operate machinery

should be cautious because the drug can cause tremor, hypoglycemia , fever, headache , chest tightness, chest drum.

pregnancy

Morihepamine's safety in pregnant women has not been determined.

Therefore, this product should not be used for pregnant women, suspected pregnancy unless the expected benefits are greater than the potential risk.

breastfeeding period

Morihepamin's safety in breastfeeding women has not been determined.

Therefore, this product should not be used for nursing women, unless the expected benefits are greater than the potential risk.

Drug interaction

There is no report on interaction with other drugs.

Storage

Store at room temperature, below 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.